Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Jun 24, 2016
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Funding Opportunity

SU2C, Merck Taking Proposals For New Uses for Keytruda 

 

Stand Up To Cancer announced a request for proposals under SU2C Catalyst, a program supporting clinical trials and translational research.

Funded in collaboration with Merck, the grants will support investigation of new uses of the company’s anti-PD-1 therapy, Keytruda (pembrolizumab), alone or in combination with other agents from Merck or other companies.

Proposals for the Merck project grants must be submitted to the American Association for Cancer Research, SU2C’s scientific partner, by July 20. The RFP and complete details are available at Proposal Central. AACR will administer the program.

Merck support for SU2C Catalyst is expected to enable as many as four projects with funding in the range of $1 million to $3 million each.

Keytruda is indicated in the U.S. for the treatment of patients with unresectable or metastatic melanoma; and for non-small cell lung cancer tumors expressing PD-L1, with disease progression on or after platinum-containing chemotherapy.

The project must include pembrolizumab alone or in combination with other compounds, biologics, diagnostics, or devices intended as therapeutic interventions, and/or methods for biomarker identification for any cancer. The project is not limited to Merck products, however. If a product is proposed for use that is marketed or is under development by another company, SU2C plans to facilitate the necessary collaborative agreements.



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter